Inozyme price target lowered to $11 from $14 at Wells Fargo

Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Inozyme (INZY) to $11 from $14 and keeps an Overweight rating on the shares. The firm said on Friday that infant data are largely supportive, with likely limited potential ADA impact read-through to ENERGY-3. ABCC6 trial design alignment is positive but will likely take a back seat given resources, Wells notes, adding that runway and visibility into early-26 ENERGY-3 remain the focus.